Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: ValuEngine, Inc.
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarin Corporation PLC says FDA delays decision on Vascepa trial design-Reuters

Wednesday, 15 Jan 2014 05:55pm EST 

Amarin Corporation PLC:Says U.S. health regulators delayed their decision to reconsider a rescinded agreement that could support a marketing application for an expanded use of the company's blood fat-lowering drug-Reuters.Says the U.S. Food and Drug Administration had in October revoked a Special Protocol Assessment (SPA) agreement covering a large late-stage trial of the drug, Vascepa.Says following an appeal from Amarin, the regulator said it would determine by Jan 15 whether it would reconsider that decision. 

Related Company News

Company Quote

0.02 +1.94%
18 Dec 2014